Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

Inclusion Criteria: * Newly initiated nintedanib during 10/01/2014 to 12/31/2018 * Were at least 66 years old as of the date of their first nintedanib prescription claim (index date) * Qualified for Medicare based on age * Had at least 12 months of continuous enrollment in Medicare Parts A, B and D before (baseline period) and 12 months after the index date (follow-up period) * Had at least one inpatient or two outpatient claims (\>14 days apart) with a diagnosis code for IPF (ICD-10-CM: J84.112; ICD-9-CM: 516.31) during the baseline period Exclusion Criteria: * Had any history of pirfenidone or nintedanib use during the baseline period * Had any history of lung transplant during the baseline, index date or follow-up periods * Had any claims for skilled nursing facility, long-term care facility or hospice during the baseline, index date or follow-up period * Had evidence (≥2 ICD-9-CM or ICD-10-CM diagnosis codes on different dates) during the baseline period of any of the following conditions: lung cancer, autoimmune, or connective tissue diseases (i.e., rheumatoid arthritis (RA), sarcoidosis, systemic lupus erythematosus (SLE), dermatopolymyositis, systemic sclerosis, Sjogren's, and mixed connective tissue disease (CTD)) during the baseline period * Had dual eligibility of Medicare and Medicaid * Had history of using pirfenidone at the same time with nintedanib during follow-up